



UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

Washington, B.O. 20201

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		A.	TTORNEY DOCKET NO.
09/632,098	08/02/00	SHEPPARD		P	99-39
_		e pea a company of company of	EXAMINER		XAMINER
HM12/0: ROBYN ADAMS			; 6	PAK, Y	
ZYMOGENETICS			ART UNIT	PAPER NUMBER	
1201 EASTLA SEATTLE WA	KE AVENUE E 98102	AST	•	1652	5

DATE MAILED:

02/16/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

		Application No.	Applicant(s)
Office Action Summary		09/632,098	SHEPPARD ET AL.
		Examiner	Art Unit
	The MAIL INC DATE of this communication on	Yong Pak	th the correspondence address
Period	The MAILING DATE of this communication ap for Reply	pears on the cover sheet wi	ui the correspondence address
TH - E a - If - If - F - A	EMORTENED STATUTORY PERIOD FOR REP E MAILING DATE OF THIS COMMUNICATION interests of time may be available under the provisions of 37 CFR fter SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a real NO period for reply is specified above, the maximum statutory period allure to reply within the set or extended period for reply will, by stating reply received by the Office later than three months after the mail armed patent term adjustment. See 37 CFR 1.704(b).	I. 1.136 (a). In no event, however, may a eply within the statutory minimum of thi bd will apply and will expire SIX (6) MOI ute, cause the application to become A	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
1)[_		
2a)[—— This action is non-final.	
3)[wance except for formal ma	
Dispos	sition of Claims	·	
4)[☑ Claim(s) <u>1-20</u> is/are pending in the applicati	on.	
	4a) Of the above claim(s) is/are withdo	rawn from consideration.	
5)[Claim(s) is/are allowed.		
6)[Claim(s) is/are rejected.	. *	
7)[Claim(s) is/are objected to.	•	·
8)[\boxtimes Claims <u>1-20</u> are subject to restriction and/o	r election requirement.	
Applic	ation Papers		
9)[☐ The specification is objected to by the Exam	iner	
10)[The drawing(s) filed on is/are objecte	d to by the Examiner.	
11)[The proposed drawing correction filed on	is: a) approved b)	disapproved.
12)[☐ The oath or declaration is objected to by the	Examiner.	
Priorit	y under 35 U.S.C. § 119		•
	Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C.	§ 119(a)-(d) or (f).
, -	a) ☐ All b) ☐ Some * c) ☐ None of:		
	1 Certified copies of the priority docume	ents have been received.	•
	2. Certified copies of the priority docume		Application No
	3. Copies of the certified copies of the pr		•
	application from the International I * See the attached detailed Office action for a li	Bureau (PCT Rule 17.2(a)).	1
	Acknowledgement is made of a claim for do		
-,_			•
Attachn	nent(c)		
	Notice of References Cited (PTO-892)	18) 🔲 Intervie	w Summary (PTO-413) Paper No(s)
	Notice of References Cited (PTO-692) Notice of Draftsperson's Patent Drawing Review (PTO-948)		of Informal Patent Application (PTO-152)

Application/Control Number: 09/632,098

Art Unit: 1652

DETAILED ACTION

Claims 1-20 are pending.

Examiner notes an apparent typographical error. "b)" is typed where claim 13 appears to be intended.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-4, 6-7, 13 and 19, drawn to protease, classified in class 435, subclass 212.
- II. Claims 5, 8-12 and 20, drawn to DNA encoding protease, vector containing said DNA, cell comprising thereof and a method for producing protease classified in class 435, subclass 212.
- III. Claim 14-16, drawn to antibody against protease and a method of producing said antibody, classified in class 530, subclass 387.9.
- IV. Claims 17-18, drawn to a method of modulating cell-cell interaction, classified in class 435, subclass 23.

The inventions are distinct, each from the other because of the following reasons:

Invention I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process can be

Application/Control Number: 09/632,098

Art Unit: 1652

practiced with receptors and ligands present on the surface of cells. Furthermore, the polypeptides of Invention I can be used in the production of antibodies.

Inventions I-III are patentably distinct because a protein, a DNA and an antibody, each with its own chemical structure and function, and they have different utilities. A DNA molecule of inventions II is not limited in use to the production of polypeptide of Invention I and can be used as a hybridization probe, and protein of invention II can be obtained by a materially different method such as by biochemical purification. The structure of an antibody of Invention III is not predictable from the structure of the protein of invention II and an antibody can cross-react with various proteins.

The methods of Inventions II, III and IV are patentably distinct as employing different products. Invention II uses DNA, Invention III uses an enzyme and Invention IV uses a cell and polypeptides.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter, restriction for examination purposes as indicated is proper.

A telephone call was made to Ms. Adams on January 29, 2001 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

A 111 ': 4050

Art Unit: 1652

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 703-308-9363. The examiner can normally be reached on Monday through Friday from 8:30 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy, can be reached on (703) 308-3804. The fax phone number for the organization where this application or proceeding is assigned is 703-308-4534.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Yong Pak
Patent Examiner

ELIZABETH SLOBODYANSKY, PH.D. PRIMARY EXAMINER

February 14, 2001